Clinical Trials in Slovenia

• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended
  2023-504753-12-00 Phase III Lung Cancer, Non-Small Cell Glaxosmithkline Research & Development Limited
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended
  2023-503923-24-00 Phase III Sjögren’s Syndrome With Moderate-toSevere Symptom State Horizon Therapeutics Ireland Designated Activity Company
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Ended
  2022-502980-39-00 Phase III Estrogen receptor (ER)-positive, HER2-negative advanced brea… F. Hoffmann-La Roche AG
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended
  2022-501939-16-00 Phase III Heart failure (HF) with mildly reduced ejection fraction (HF… Novo Nordisk A/S
• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended
  2024-510742-13-00 Phase III Pediatric low-grade glioma harboring an activating RAF alter… Day One Biopharmaceuticals Inc.
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended
  2023-504741-32-00 Phase II Moderately to Severely Active Crohn's Disease Janssen - Cilag International
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended
  2023-504743-13-00 Phase II Moderately to Severely Active Ulcerative Colitis Janssen - Cilag International
• A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria Ended
  2023-509229-31-00 Phase III Metabolic Disorders - Phenylketonuria PTC Therapeutics Inc.
• A research study to compare somapacitan once a week with Norditropin® once a day in children who need help to grow Ended
  2023-506927-27-00 Phase III Children with short stature either born small for gestationa… Novo Nordisk A/S
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended
  2023-509372-41-00 Phase III Multiple Sclerosis Novartis Pharma AG
• A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscu… Ended
  2024-511492-15-00 Phase III Duchenne Muscular Dystrophy Sarepta Therapeutics Inc.
• Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended
  2023-507974-42-00 Phase II Moderate to Severe Ulcerative Colitis Abivax
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended
  2024-510735-21-00 Phase III Atherosclerotic cardiovascular disease (ASCVD) Novartis Pharma AG
• A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim… Ended
  2023-508690-92-00 Phase III/IV IgA Nephropathy Novartis Pharma AG
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended
  2023-504734-21-00 Phase III Psoriatic arthritis (PsA) Janssen - Cilag International
• PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll… Ended
  2024-511321-54-00 Phase III intermediate-high-risk acute pulmonary embolism Assistance Publique Hopitaux De Paris
• A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously … Ended
  2023-503229-21-00 Phase III Unresectable hepatocellular carcinoma (HCC) F. Hoffmann-La Roche AG
• A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects … Ended
  2023-505170-15-00 Phase III Adult Subjects With Late Onset Pompe Disease (LOPD) Amicus Therapeutics Inc.
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended
  2023-508292-37-00 Phase III Cardiovascular Disease Novartis Pharma AG
• A global study of midostaurin in combination with chemotherapy to evaluate safety, efficacy, and pharmacokinetics in newly diagnosed pediatr… Ended
  2023-509834-20-00 Phase II untreated FLT3-mutated Acute Myeloid Leukemia Novartis Pharma AG
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended
  2023-506994-36-00 Phase III Ulcerative Colitis AbbVie Deutschland GmbH & Co. KG
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended
  2023-507889-89-00 Phase III Respiratory tract infection Universitair Medisch Centrum Utrecht
• Study of efficacy and safety of JDQ443 in comparison with docetaxel in participants with locally advanced or metastatic KRAS G12C mutant non… Halted
  2023-510082-10-00 Phase III Advanced non-small cell lung cancer harboring the KRAS G12C … Novartis Pharma AG
• A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety … Suspended
  2024-511244-12-01 Phase III Amyotrophic Lateral Sclerosis Ab Science

Showing 49–72 of 100 trials